Cerus Other Long-Term Assets 2010-2024 | CERS
Cerus other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
| Cerus Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024 | $18 |
| 2023 | $13 |
| 2022 | $8 |
| 2021 | $24 |
| 2020 | $10 |
| 2019 | $7 |
| 2018 | $7 |
| 2017 | $4 |
| 2016 | $4 |
| 2015 | $3 |
| 2014 | $1 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $1 |
| 2010 | $1 |
| 2009 | $1 |
| Cerus Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024-12-31 | $18 |
| 2024-09-30 | $16 |
| 2024-06-30 | $15 |
| 2024-03-31 | $13 |
| 2023-12-31 | $13 |
| 2023-09-30 | $12 |
| 2023-06-30 | $24 |
| 2023-03-31 | $23 |
| 2022-12-31 | $8 |
| 2022-09-30 | $26 |
| 2022-06-30 | $26 |
| 2022-03-31 | $22 |
| 2021-12-31 | $24 |
| 2021-09-30 | $14 |
| 2021-06-30 | $11 |
| 2021-03-31 | $12 |
| 2020-12-31 | $10 |
| 2020-09-30 | $7 |
| 2020-06-30 | $7 |
| 2020-03-31 | $7 |
| 2019-12-31 | $7 |
| 2019-09-30 | $7 |
| 2019-06-30 | $7 |
| 2019-03-31 | $8 |
| 2018-12-31 | $7 |
| 2018-09-30 | $7 |
| 2018-06-30 | $7 |
| 2018-03-31 | $7 |
| 2017-12-31 | $4 |
| 2017-09-30 | $4 |
| 2017-06-30 | $5 |
| 2017-03-31 | $4 |
| 2016-12-31 | $4 |
| 2016-09-30 | $3 |
| 2016-06-30 | $3 |
| 2016-03-31 | $3 |
| 2015-12-31 | $3 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $1 |
| 2014-12-31 | $1 |
| 2014-09-30 | $0 |
| 2014-06-30 | $0 |
| 2014-03-31 | $0 |
| 2013-12-31 | $0 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $0 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $0 |
| 2011-12-31 | $1 |
| 2011-09-30 | $1 |
| 2011-06-30 | $1 |
| 2011-03-31 | $1 |
| 2010-12-31 | $1 |
| 2010-09-30 | $1 |
| 2010-06-30 | $1 |
| 2010-03-31 | $1 |
| 2009-12-31 | $1 |
| 2009-09-30 | $1 |
| 2009-06-30 | $1 |
| 2009-03-31 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.258B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||